Format

Send to

Choose Destination
See comment in PubMed Commons below
Stroke. 2012 Feb;43(2):599-606. doi: 10.1161/STROKEAHA.111.628867. Epub 2011 Dec 15.

von Willebrand factor: an emerging target in stroke therapy.

Author information

1
Immune Disease Institute, Children's Hospital Boston, Boston, MA, USA. simon.demeyer@kuleuven-kortrijk.be

Abstract

Thrombus formation is of paramount importance in the pathophysiology of acute ischemic stroke. Current antithrombotics used to treat or prevent cerebral ischemia are only moderately effective or bear an increased risk of severe bleeding. von Willebrand factor (VWF) has long been known to be a key player in thrombus formation at sites of vascular damage. While the association between VWF and coronary heart disease has been well studied, knowledge about the role of VWF in stroke is much more limited. However, in recent years, an increasing amount of clinical and preclinical evidence has revealed the critical involvement of VWF in stroke development. This review summarizes the latest insights into the pathophysiologic role of VWF-related processes in ischemic brain injury under experimental conditions and in humans. Potential clinical merits of novel inhibitors of VWF-mediated platelet adhesion and activation as powerful and safe tools to combat thromboembolic disorders including ischemic stroke are discussed. Preclinical and clinical evidence illustrates an important role of VWF in ischemic stroke, suggesting that VWF could become a promising target in stroke therapy.

PMID:
22180250
PMCID:
PMC4102321
DOI:
10.1161/STROKEAHA.111.628867
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center